Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
2015/11/05 by Marie Vétizou, Jonathan M. Pitt, Romain Daillère +45 · 53 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Gut microbiota and health #Clostridium difficile and Clostridium perfringens research #Tryptophan and brain disorders
paper · doi:10.1126/science.aad1329
Abstract
Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.
Cited by
- Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
- The genetic background of inflammatory bowel disease: from correlation to causality
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
- Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice
- Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
- Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review
- Bacteria-based immune therapies for cancer treatment
- The gut microbiome and cancer response to immune checkpoint inhibitors
- The microbiome and human cancer
- The hidden mycobiome: emerging role in anticancer immunotherapy
- Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology
- Gut Microbiota Modulation through <i>Akkermansia</i> spp <i>.</i> Supplementation Increases CAR T-cell Potency
- Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer
- Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy
- Microbiome‐driven anticancer therapy: A step forward from natural products
- Interaction between microbiota and immunity in health and disease
- Gut Microbiota–Related Biomarkers in Immuno-Oncology
- The danger theory of immunity revisited
- Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- Microbiota in health and diseases
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity
- Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature
- Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
- Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications
- Could the Spike Protein Derived from mRNA Vaccines Negatively Impact Beneficial Bacteria in the Gut?
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. [europepmc]
- Metabolomics: beyond biomarkers and towards mechanisms. [europepmc]
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. [europepmc]
- Tumour-associated macrophages as treatment targets in oncology. [europepmc]
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. [europepmc]
- Influence of diet on the gut microbiome and implications for human health. [europepmc]
- Homeostatic Immunity and the Microbiota. [europepmc]
- Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. [europepmc]
- Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. [europepmc]
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. [europepmc]
- CTLA-4: a moving target in immunotherapy. [europepmc]
- The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. [europepmc]
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. [europepmc]
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. [europepmc]
- Understanding the tumor immune microenvironment (TIME) for effective therapy. [europepmc]
- Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. [europepmc]
- Human gut microbiome: hopes, threats and promises. [europepmc]
- The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. [europepmc]
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. [europepmc]
- Comprehensive review of targeted therapy for colorectal cancer. [europepmc]
- Interaction between microbiota and immunity in health and disease. [europepmc]
- The microbiome and human cancer. [europepmc]
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. [europepmc]
- Microbiota in health and diseases. [europepmc]
- Macrophages as tools and targets in cancer therapy. [europepmc]
Related